Superluminal Medicines Raises $60M Series B to Advance Obesity Drug

Superluminal Medicines secured $60M in a Series B round led by BVF Partners to advance its selective MC4R agonist drug for rare genetic obesity into Phase 1 trials by end of 2026. The funding will also expand its GPCR-focused AI-driven drug discovery platform.